Logo

Vivus Reports Results of Qsymia in Pilot Clinical Study for Patients with Laparoscopic Sleeve Gastrectomy Surgery

Share this

Vivus Reports Results of Qsymia in Pilot Clinical Study for Patients with Laparoscopic Sleeve Gastrectomy Surgery

Shots:

  • The pilot clinical study involves assessing of Qsymia (phentermine and topiramate ER caps) in 25 patients with a BMI of 50+ who were planning to undergo LSG vs patients undergoing surgery alone without anti-obesity medication (AOM)
  • The clinical study results: @24mos. BMI (33.8 kg/m2 vs 42 kg/m2); average wt. loss (28.1 kg vs 12.3 kg); @2yrs. post LSG (11.2% vs -18.2%); BMI<40 @24 post LSG (61.5% vs. 47.5%); wt. loss more than twice as much weight during preoperative treatment
  • Qsymia is an anti-obesity therapy indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults BMI of 30 kg/m2+ or 27 kg/m2+ with at least one weight-related medical condition such as high BP- T2D or high cholesterol

Click here to­ read full press release/ article | Ref: Vivus | Image: Vivus


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions